301 related articles for article (PubMed ID: 35694999)
21. Corticosteroid-refractory autoimmune hepatitis after COVID-19 vaccination: a case report and literature review.
Ueno M; Takabatake H; Itakura J; Fujita R; Kayahara T; Morimoto Y; Notohara K; Mizuno M
Clin J Gastroenterol; 2023 Aug; 16(4):554-558. PubMed ID: 37029249
[TBL] [Abstract][Full Text] [Related]
22. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
Casas Fischer R
Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
[TBL] [Abstract][Full Text] [Related]
23. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
[TBL] [Abstract][Full Text] [Related]
24. Autoimmune hepatitis with history of HCV treatment triggered by COVID-19 vaccination: case report and literature review.
Hasegawa N; Matsuoka R; Ishikawa N; Endo M; Terasaki M; Seo E; Tsuchiya K
Clin J Gastroenterol; 2022 Aug; 15(4):791-795. PubMed ID: 35716255
[TBL] [Abstract][Full Text] [Related]
25. Autoimmune hepatitis after SARS-CoV-2 vaccine: New-onset or flare-up?
Avci E; Abasiyanik F
J Autoimmun; 2021 Dec; 125():102745. PubMed ID: 34781161
[TBL] [Abstract][Full Text] [Related]
26. Development of Graves' Disease After SARS-CoV-2 mRNA Vaccination: A Case Report and Literature Review.
Lui DTW; Lee KK; Lee CH; Lee ACH; Hung IFN; Tan KCB
Front Public Health; 2021; 9():778964. PubMed ID: 34888290
[No Abstract] [Full Text] [Related]
27. Optic Neuritis After SARS-CoV-2 Vaccination.
Shemer A; Greenbaum A; Toledano A; Biron R; Dubinsky-Pertzov B; Or L
J Neuroophthalmol; 2023 Mar; 43(1):29-33. PubMed ID: 36790061
[TBL] [Abstract][Full Text] [Related]
28. Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study.
Tamura T; Ninomiya K; Kubo T; Kuyama S; Tachibana S; Inoue K; Chikamori K; Kudo K; Ochi N; Harada D; Maeda Y; Kiura K
Thorac Cancer; 2022 Feb; 13(3):453-459. PubMed ID: 34964270
[TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC).
Gauci ML; Coutzac C; Houot R; Marabelle A; Lebbé C;
Eur J Cancer; 2021 May; 148():121-123. PubMed ID: 33743480
[No Abstract] [Full Text] [Related]
30. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
31. COVID-19 and Immune-Mediated RBC Destruction.
Jacobs JW; Booth GS
Am J Clin Pathol; 2022 Jun; 157(6):844-851. PubMed ID: 34919640
[TBL] [Abstract][Full Text] [Related]
32. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
33. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
34. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
Front Immunol; 2021; 12():704773. PubMed ID: 34220867
[TBL] [Abstract][Full Text] [Related]
35. Hemolysis induced by SARS-CoV-2 mRNA vaccination in patients with paroxysmal nocturnal hemoglobinuria.
Kamura Y; Sakamoto T; Yokoyama Y; Nishikii H; Sakata-Yanagimoto M; Chiba S; Obara N
Int J Hematol; 2022 Jul; 116(1):55-59. PubMed ID: 35668275
[TBL] [Abstract][Full Text] [Related]
36. Finally, an FDA Approval for an Immunization Against COVID-19: Hope on the Horizon.
Powell J; Piszczatoski CR
Ann Pharmacother; 2022 Sep; 56(9):1058-1064. PubMed ID: 35012364
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of hematological parameters and thrombocytopenia following Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccination.
Algaissi A; Alamer E; Jeraiby M; Alomaish A; Elrhima O; Qumayi S; Qasir NA; Areeshi H; Masmali A; Alhazmi A
Saudi Med J; 2022 Jun; 43(6):567-571. PubMed ID: 35675927
[TBL] [Abstract][Full Text] [Related]
38. Safety of anti-SARS-CoV-2 messenger RNA vaccine in lung cancer patients undergoing anticancer chemotherapy: A multicenter, prospective, observational, patient-reported outcome study.
Harada D; Tamura T; Ninomiya K; Kubo T; Kuyama S; Tachibana S; Inoue K; Chikamori K; Kudo K; Ochi N; Maeda Y; Kiura K
Thorac Cancer; 2023 Jan; 14(3):231-236. PubMed ID: 36404396
[TBL] [Abstract][Full Text] [Related]
39. Extensive Cerebral Venous Sinus Thrombosis (CVST) After the First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine without Thrombotic Thrombocytopenia Syndrome (TTS) in a Healthy Woman.
Alhashim A; Hadhiah K; Al Khalifah Z; Alhaddad FM; Al ARhain SA; Bin Saif FH; Abid A; Al Gamdi O; Alsulaiman F; AlQarni M
Am J Case Rep; 2022 Feb; 23():e934744. PubMed ID: 35136010
[TBL] [Abstract][Full Text] [Related]
40. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
Pillay J; Gaudet L; Wingert A; Bialy L; Mackie AS; Paterson DI; Hartling L
BMJ; 2022 Jul; 378():e069445. PubMed ID: 35830976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
